Objective:

To discuss the evolving diagnostic landscape in cystic fibrosis (CF) and highlight opportunities for addressing unmet needs in diagnosing and managing lung infections.

Approach:

• Diagnostic Challenges: The introduction of CFTR modulator therapies has transformed CF care but has also limited sputum production, complicating traditional diagnostic methods.
• Need for New Diagnostics: There is a need for innovative diagnostic approaches that provide actionable information, utilize alternative sample types, and are suitable for point-of-care use.
• Role of CF AMR Syndicate: The CF AMR Syndicate connects developers with resources and expertise to address diagnostic challenges and accelerate the development of new technologies.

Key Findings:

• CFTR modulator therapies have reduced sputum production, complicating infection detection.
• Traditional symptoms of pulmonary exacerbations are becoming less reliable.
• New diagnostic tools are needed to distinguish between active infections and chronic colonization.

Limitations:

• Current diagnostic methods may not effectively identify infections due to reduced sputum production.
• The reliance on traditional symptoms for recognizing health deterioration is becoming less effective.

Conclusion:

Innovative diagnostic solutions are essential for improving infection management in CF, and the CF AMR Syndicate plays a crucial role in facilitating this development.

Sources:

• CF AMR Syndicate